GO
Loading...

Merck & Co Inc

More

  • Glaxo's Avandia Hits The Bottom Line--Hard Thursday, 7 Feb 2008 | 12:43 PM ET

    Shares of GlaxoSmithKline this morning are getting hammered because the company announced it expects earnings per share to fall by a mid-single digit percentage this year. Analysts thought they'd grow by three percent.

  • Cramer's Search for Snow White Monday, 4 Feb 2008 | 6:58 PM ET

    Mirror, mirror, on the wall -- what the heck is going on in the markets?Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Recession Fears Knock Stocks Monday, 4 Feb 2008 | 6:23 PM ET

    Stocks lost ground Monday, coming off their best week in nearly five years. What's the word on the Street?

  • American Express Drags Down Blue Chips Monday, 4 Feb 2008 | 4:54 PM ET

    Stocks closed lower, led by financials, after brokers downgraded several big names in the sector, including American Express.

  • Glaxo, Merck, SGP & Amgen: Readers Have a Lot to Say Friday, 1 Feb 2008 | 10:51 AM ET

    It's a new month. Time to clean out the inbox. Regarding my post earlier this week about Sen. Chuck Grassley's office breaking the "Nature" embargo on the leak of the GlaxoSmithKline Avandia study, I heard from the "Nature" article reporter.

  • Stocks Rally But Still Have Dismal Month Thursday, 31 Jan 2008 | 5:41 PM ET

    Stocks closed with a big rally, led by beaten-down financial shares, but still ended one of the worst Januarys in years.

  • Stocks Close Lower After Fed Rally Fizzles Wednesday, 30 Jan 2008 | 3:28 PM ET

    A stock rally fueled by the Fed's latest interest rate cut lost momentum in the final hour after CNBC reported that two big bond insurers could be downgraded as early as today.

  • Roche Profit Rises on Sales of Cancer Drugs Wednesday, 30 Jan 2008 | 1:10 PM ET

    European pharmaceutical Roche reported a better-than-expected 25 percent increase in fourth-quarter net profit Wednesday on strong sales of its cancer drugs, despite lower sales of its key influenza drug Tamiflu.

  • Merck: Why's Stock So Low? (And What Am I Missing?) Wednesday, 30 Jan 2008 | 12:10 PM ET

    Dow component Merck beat the Street with fourth quarter results on earnings per share (revenue was a sliver below the analyst consensus) and reaffirmed its earnings guidance for this year. Maybe the beaten-down stock is falling victim to another pre-Fed interest rate decision market downdraft...

  • Merck Swings to Loss on Vioxx Charges, Shares Fall Wednesday, 30 Jan 2008 | 10:42 AM ET

    Merck on Wednesday reported a fourth-quarter loss due to charges from a costly settlement related to its withdrawn Vioxx arthritis drug, but results soundly beat Wall Street forecastsand lifted its shares 2 percent.

  • Your First Move For Wednesday Jan. 30th Tuesday, 29 Jan 2008 | 7:37 PM ET

    Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!

  • Losing Hope Monday, 28 Jan 2008 | 6:48 PM ET

    Big Pharma's fortunes rise and fall on the ability to sell hope. Is there any hope for the stocks that trade on hope?

  • Stocks to Nibble At While Waiting for Market Bottom Monday, 28 Jan 2008 | 4:19 PM ET

    Recession. Bear market. Credit crunch. Is it better to stay out of the stock market or use the recent selloff as a buying opportunity?

  • In what I would describe as a pretty extraordinary filing with the Securities and Exchange Commission, Schering-Plough is putting in black and white the date and time that senior level executives were informed about the results of the controversial ENHANCE study of the cholesterol drug Vytorin.

  • FDA Speaks on Merck & Schering's Vytorin Friday, 25 Jan 2008 | 6:59 PM ET

    I listened in to the hour-long Food and Drug Administration conference call with reporters regarding Vytorin, and I wanted to pass along a few highlights...

  • Stop Trading!: Vytorin Panic = Buy Friday, 25 Jan 2008 | 3:45 PM ET

    Merck and Schering-Plough are being sold off in a classic case of headline overreaction, Cramer says. Don't fall for it.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Merck And Schering Reeling From Vytorin Study Thursday, 24 Jan 2008 | 1:56 PM ET

    ImpactRx--which follows prescription writing for the industry, investors and analysts--is out with a press release this afternoon assessing the damage to Merck and Schering-Plough's cholesterol franchise of Vytorin and Zetia.

  • Ladies' Night Web Extra: Part 1 Wednesday, 23 Jan 2008 | 2:24 PM ET

    The show was over, but Cramer kept going. Don't miss his in-depth answers to audience questions about Merck, Target and more.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Pfizer Doing Its "Best" To Help Dow And Pharma Sector Wednesday, 23 Jan 2008 | 11:27 AM ET

    As I write this at the start of the second hour of regular trading, Pfizer is hangin' on to a small gain. It's the only big pharma stock trading higher this morning and for a moment after the opening bell it was the only Dow component in the green. (Merck and Schering-Plough, still reeling from the Vytorin/Zetia study, are getting pummeled again in the early going--each down more than a buck.)

  • Pfizer Tops Views; Shares Pressured by Sector Selloff Wednesday, 23 Jan 2008 | 10:12 AM ET
    Lipitor

    Pfizer Wednesday reported a higher-than-expected fourth-quarter profit, helped by lower taxes, a weak dollar and growing demand for its drugs for nerve pain, kidney cancer and smoking cession.